The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) opened 11.18% higher. As of press release, it had risen 11.18% to HK$8.75, with a turnover of HK$1.184,800.

According to the news, Yingpai Pharmaceutical issued an announcement stating that the board of directors decided to use no more than HK$100 million to buy back H shares in the open market, and that all required capital came from the company's own funds. Furthermore, depending on market conditions, the company may further repurchase H shares within the scope of the repurchase authorization granted by the shareholders' meeting. The company will then cancel all or part of the H shares repurchased and/or hold them as treasury shares in accordance with the arrangements deemed appropriate by the board of directors, in accordance with applicable laws and regulations and the “Listing Rules”.

Since the company's Hong Kong stock listing, the company has continued to advance its global R&D and commercialization layout around the cancer field: Senapali received positive opinions from the European Medicines Agency (EMA) Committee on Human Medicines (CHMP) in September; the 2026 ESMO annual conference showcased the latest clinical data for many core products in the form of posters; and next-generation dual-load ADC and targeted protein degradation technology platforms have entered the pre-clinical stage.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.